Induction of antitumor immunity by nanoparticle incorporating alpha-galactocylceramide
| Project/Area Number |
24790037
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
NAKAMURA Takashi 北海道大学, 薬学研究科(研究院), 助教 (20604458)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | ドラッグデリバリー / リポソーム / ワクチン / 癌免疫療法 / 脂質抗原 / デリバリーシステム / 癌免疫 |
|---|
| Research Abstract |
Alpha-galactosylceramide (GC), a lipid antigen present on CD1d molecules, is predicted to have clinical applications as a new class of adjuvant, because GC strongly activates natural killer T (NKT) cells which produce large amounts of IFN-gamma. Here, we incorporated GC into stearylated octaarginine-modified liposomes (R8-Lip), our original delivery system developed for vaccines, and investigated the effect of nanoparticulation. The nanopaticulation of GC enhanced the GC presentation on CD1d of antigen presenting cells, NKT proliferation, IFN-gamma production, therapeutic effect against highly malignant B16 melanoma. These results strongly indicate that the nanopaticulation of GC by R8-Lip is promising technique for achieving systemic GC therapy.
|
Report
(3 results)
Research Products
(12 results)
